XENE

Rating neutralAI Memo

Xenon

As of 2026-09-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-26 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

X-NOVA2 depression readout • 2027-03-31

Base target: $38 / p=45% prob

Biggest risk

The safety-related enrollment pause could delay or diminish the depression opportunity. X-NOVA2 is smaller than initially planned, and neither a mitigation plan nor an enrollment-resumption date is established. [#IR-2026-09-17]

Invalidation

Break below $20 or thesis failure.

What would change my mind?

The submitted focal-seizure application preserves a potential first-launch pathway, while a tolerable dosing approach and positive X-NOVA2 data could restore some psychiatry optionality. Xenon reported $1.2 billion in cash and marketable securities at Q2 and projected runway into 2029. [#SEC-8K-2026-08-06] [#IR-2026-09-17]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-26

Base target

$38

p=45%

Bull target

$60

p=20%

Bear target

$20

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Psychiatry-study safety review
FDA review of azetukalner for focal seizures
The submitted focal-seizure application preserves a potential first-launch pathway, while a tolerable dosing approach and positive X-NOVA2 data could restore some psychiatry optionality.

BearKey bullets

FDA review timing, approval, labeling, and eventual epilepsy uptake remain uncertain.
Multiple trials and launch preparation can increase spending; the reported runway is a company projection, not a guarantee.
[#SEC-8K-2026-08-06]

WatchKey bullets

X-NOVA2 depression readout

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $38 (p=45%)

Target spread vs base: +58% / -47%

Scenario probabilities

Bull Target: $60 (p=20%)Base Target: $38 (p=45%)Bear Target: $20 (p=35%)

Commentary

September coverage reports an approximately 30% one-day selloff after the psychiatry pause; the packet's September 25 adjusted-close anchor is $36.94. Proactive coverage News tone is negative despite the application submission. Analyst-revision evidence is insufficient to establish a post-event consensus. Social, options, short-interest, and employee data were unavailable; their zero fields are placeholders, not neutral readings.

As of 2026-09-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Psychiatry-study safety review
FDA review of azetukalner for focal seizures

Scenarios

Bull Target (Scenario probability)

$60 / p=20% prob

Base Target (Scenario probability)

$38 / p=45% prob

Bear Target (Scenario probability)

$20 / p=35% prob

Analysis 2026-09-26 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.80

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
X-NOVA2 depression readout
Enrollment ended at about 360 patients, roughly 80% of the original target. Xenon expects topline data in Q1 2027 and considers the study sufficiently powered, but efficacy and tolerability remain uncertain following the safety-related pause. [#IR-2026-09-17] Company release
Prob 70.00% • Move 30.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Psychiatry-study safety review
2026-12-31
Xenon paused new enrollment in its depression studies after neuropsychiatric adverse events and is evaluating dosing changes with its safety-monitoring board. Existing participants remain on study; no date for resuming enrollment was given. Year-end is a monitoring estimate, not company guidance. [#IR-2026-09-17] Company release
Prob 40% • Move 15% • Priced-in 55%

Long-term Catalysts

Months to a year

FDA review of azetukalner for focal seizures
2027-09-30
Xenon submitted the application supported by X-TOLE and X-TOLE2; its other epilepsy studies continue enrolling. FDA acceptance and an action date have not been announced. The date below is an analyst monitoring estimate, not an FDA or company timeline. [#IR-2026-09-17] [#SEC-8K-2026-08-06] Company release
Prob 65% • Move 25% • Priced-in 50%

Risks

FDA review timing, approval, labeling, and eventual epilepsy uptake remain uncertain.
Multiple trials and launch preparation can increase spending; the reported runway is a company projection, not a guarantee. [#SEC-8K-2026-08-06]
Neuropsychiatric adverse events may require dose changes, further pauses, or narrower development in depression. [#IR-2026-09-17]
X-NOVA2 efficacy and tolerability remain unproven despite management's assessment of statistical power. [#IR-2026-09-17]

Peers

Symbol	Summary
ACAD	A CNS-focused commercial-stage comparator from the candidate set; its established products make direct valuation comparisons with Xenon's prelaunch profile limited.
BHVN	Prior baseline identifies Biohaven's Kv7 focal-epilepsy program as a mechanism and indication comparator; development timing and portfolio breadth differ.
PRAX	Prior baseline identifies Praxis as a neuroscience and epilepsy-development comparator, not a like-for-like valuation peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-26

Loading AI feed…

Symbol

Summary

ACAD

A CNS-focused commercial-stage comparator from the candidate set; its established products make direct valuation comparisons with Xenon's prelaunch profile limited.

BHVN

Prior baseline identifies Biohaven's Kv7 focal-epilepsy program as a mechanism and indication comparator; development timing and portfolio breadth differ.

PRAX

Prior baseline identifies Praxis as a neuroscience and epilepsy-development comparator, not a like-for-like valuation peer.